Using biomarkers to predict oxidative stress in atrial fibrillation
Prediction of UA/SOD Ratio as a Biomarker of Oxidative Stress in Atrial Fibrillation
This study is trying to see if certain blood markers can help predict oxidative stress in people with atrial fibrillation to improve diagnosis and prevention.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Qianfoshan Hospital Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06119802 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the predictive effects of uric acid and superoxide dismutase as biomarkers of oxidative stress in patients with atrial fibrillation (AF). By analyzing blood markers related to oxidative stress, the study seeks to clarify their relationship with AF and provide insights for better diagnosis and prevention strategies. The research focuses on hospitalized patients diagnosed with AF between January 2018 and December 2020, utilizing data from electrocardiography and Holter monitoring. The findings may contribute to understanding the pathophysiological mechanisms of AF and inform future treatment approaches.
Who should consider this trial
Good fit: Ideal candidates for this study are hospitalized patients diagnosed with atrial fibrillation during the specified time frame.
Not a fit: Patients with acute heart failure, acute myocardial infarction, severe liver or kidney dysfunction, malignant tumors, or missing baseline laboratory data may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the diagnosis and prevention of atrial fibrillation through better understanding of oxidative stress biomarkers.
How similar studies have performed: While there is growing interest in the role of oxidative stress in atrial fibrillation, this specific approach to using comprehensive biomarkers is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: This retrospective study enrolled all hospitalized patients from January 2018 to December 2020 at the Department of Cardiology in The First Affiliated Hospital of Shandong First Medical University. The diagnosis of AF was based on 12-lead electrocardiography (ECG) or 24-hour Holter monitoring, and classification was based on the published 2020 ESC guidelines for the diagnosis and management of AF. Exclusion Criteria: 1. acute heart failure and acute myocardial infarction; 2. severe liver or kidney dysfunction (with aspartate aminotransferase or alanine aminotransferase levels three times higher than normal and estimated glomerular filtration rate \<30 ml/ (min\*1.73 m2)); 3. malignant tumors; 4. missing data of laboratory indicators at baseline.
Where this trial is running
Jinan, Shandong
- Shandong provincal Qianfoshan hospital — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Yinglong Hou, PhD
- Email: yujiao61@163.com
- Phone: 13791120810
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.